5th In Vivo Cell Engineering and Gene Editing Summit

Memo

Unlock the next frontier of cell and gene therapies at the 5th In Vivo Cell Engineering and Gene Editing Summit. This meeting is the leading industry forum dedicated to advancing in vivo delivery modalities, editing technologies, payload design, and translational strategies. This summit brings together pioneering scientists, biotech innovators, regulatory experts, and therapeutic developers who are shaping the future of in vivo gene engineering. The program is designed to help teams accelerate therapeutic development, overcome translational challenges, and build safer, more precise in vivo editing platforms. Key themes include:- Next-generation delivery systems for in vivo gene engineering- Advances in CRISPR, base editing, prime editing, and programmable nucleases- Novel vectors, nanoparticles, and targeted delivery strategies- Safety, durability, biodistribution, and immunogenicity considerations- Regulatory insights and clinical development pathways- Real-world case studies from leading biotech and pharma innovators Whether you're working in ex vivo and looking to add in vivo to your pipeline, or have cemented your work in in vivo already, this summit offers unparalleled access to the experts and insights driving the field forward. Join the global community pushing the boundaries of what's possible in in vivo cell engineering and gene editing, and help shape the next generation of genetic medicines. URLs:Tickets: https://go.evvnt.com/3496286-2?pid=5569Brochure: https://go.evvnt.com/3496286-3?pid=5569 Date and Time: Tuesday, 28 July 2026 at 09:00 - Thursday, 30 July 2026 at 16:30 Venue details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States Category: Conferences | Science, Health and Medicine Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4397.00,Drug Developer Pricing - 3 Day Pass (Conference + 1 Workshop): USD 3748.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3797.00,Academic Pricing - 3 Day Pass (Conference + 1 Workshop): USD 3248.00,Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,Service Provider Pricing - 3 Day Pass (Conference + Workshop Day) : USD 5297.00,Service Provider Pricing - 3 Day Pass (Conference + 1 Workshop) : USD 4548.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00 Speakers: Cecile Bauche, Founder and Chief Scientific Officer, Alaya.bio, Sidharth Kerkar, Founder and Chief Executive Officer, AllerGene AI Therapeutics, Shane Olwill, Chief Development Officer, Asgard Therapeutics, Connor Tsuchida, Scientific Co-Founder, Azalea Therapeutics, Robert Hofmeister, Chief Scientific Officer, CREATE Medicines, Brian Zhou, Associate Director, Genetic Medicine Search and Evaluation, Eli Lilly, Matt Spindler, Vice President, Research, GigaMune, Kevin Cognetti, Vice President of Corporate Strategy, Kite Pharma, Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics, Dhaval Patel, Executive Vice President and Chief Scientific Officer, Sana Biotechnology, Jason Fontenot, Chief Scientific Officer, Stylus Medicine, Haig Aghajanian, Adjunct Assistant Professor of Medicine, University of Pennsylvania, Delai Chen, Director, Nanoparticle Formulation, Beam Therapeutics, Eric Kmiec, Founder and Chief Executive Officer, CorriXR Therapeutics, Bin Wu, Founder and Chief Executive Officer, Cytodigm, George Diaz, Vice President, Urea Cycle Disorders and Therapeutic Area Lead, iECURE, Zach Zhu, Chief Technology Officer, Innorna, Birgit Schultes, Executive Vice President and Chief Scientific Officer, Intellia Therapeutics, Jenny Marlowe, Chief Development Officer, nChroma Bio